{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T13:42:30Z","timestamp":1786282950159,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Post-therapeutic [\n                      <jats:sup>131<\/jats:sup>\n                      I]NaI whole-body scintigraphy (ptWBS) is mandatory after radioiodine therapy (RAIT), but the most suitable acquisition time remains uncertain. We compared image interpretability at early and delayed time points in patients with differentiated thyroid cancer (DTC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective secondary analysis included prospectively acquired ptWBS data from 35 patients. Scans obtained at 6, 24, 48, 72, and 168\u00a0h after RAIT were independently ranked by three nuclear medicine physicians and evaluated with a 10-item criteria-based image-quality score. Rankings were analyzed using a Plackett-Luce model, and criteria-based scores were analyzed using generalized estimating equations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The analysis comprised 167 scans, 501 criteria-based ratings, and 500 intuitive rank observations. The 24-h acquisition had the highest estimated preference, followed by 48, 6, 72, and 168\u00a0h. After Holm adjustment, 24\u00a0h was favored over 6, 72, and 168\u00a0h, whereas the difference between 24 and 48\u00a0h was not significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.091). The criteria-based score was highest at 24\u00a0h (39.52; 95% CI, 38.62\u201340.43) and next-highest at 48\u00a0h (34.79); all pairwise differences in scores were significant. Each 5-point increase in the criteria-based score was associated with higher odds of a more favorable intuitive ranking (OR, 2.01; 95% CI, 1.70\u20132.38).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PtWBS acquired at 24\u00a0h provided the best overall interpretability of the images. A 48\u00a0h scan may be considered when practical or radiation-protection considerations favor later imaging, but equivalence to 24\u00a0h has not been established. Additional delayed imaging may still be useful when distant metastatic disease is suspected.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12880-026-02647-y","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:32:56Z","timestamp":1786167176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimal timing of post-therapeutic [131I]NaI whole-body scintigraphy in predominantly low- and intermediate-risk differentiated thyroid cancer: a secondary analysis of prospectively acquired data and a structured literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"Andreas","family":"Pfestroff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Wolfram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Pfestroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wadim","family":"Bowl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ebrahimifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamim","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"di Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrooz H.","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Flux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Taprogge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Luster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Eilsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"2647_CR1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00259-016-3327-3","volume":"43","author":"FA Verburg","year":"2016","unstructured":"Verburg FA, Aktolun C, Chiti A, et al. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:1001\u20135.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2647_CR2","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Krebshilfe D. AWMF). S3-Leitlinie Schilddr\u00fcsenkarzinom, Langversion 1.1, April 2026. AWMF-Registernummer 031-056OL. Available at: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/schilddruesenkarzinom. Accessed 17 July 2026."},{"key":"2647_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1\u2013133.","journal-title":"Thyroid"},{"key":"2647_CR4","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1210\/jc.2003-031167","volume":"89","author":"AM Sawka","year":"2004","unstructured":"Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170: a systematic review and meta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668\u201376.","journal-title":"J Clin Endocrinol Metab"},{"key":"2647_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2265.2008.03222.x","volume":"69","author":"AM Sawka","year":"2008","unstructured":"Sawka AM, Lakra DC, Lea J, et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf). 2008;69:479\u201390.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2647_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2967\/jnumed.124.269091","volume":"66","author":"H Weis","year":"2025","unstructured":"Weis H, et al. Impact of radioactive iodine treatment on long-term relative survival in patients with papillary and follicular thyroid cancer: a SEER-based study covering histologic subtypes and recurrence risk categories. J Nucl Med. 2025;66:525\u201330.","journal-title":"J Nucl Med"},{"key":"2647_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00259-019-04479-1","volume":"47","author":"FA Verburg","year":"2020","unstructured":"Verburg FA, et al. Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade. Eur J Nucl Med Mol Imaging. 2020;47:78\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2647_CR8","doi-asserted-by":"publisher","first-page":"17491","DOI":"10.18632\/oncotarget.24766","volume":"9","author":"A Campenn\u00ec","year":"2018","unstructured":"Campenn\u00ec A, et al. Undetectable or low (<\u20091 ng\/mL) postsurgical thyroglobulin values do not rule out metastases in early-stage differentiated thyroid cancer patients. Oncotarget. 2018;9:17491\u2013500.","journal-title":"Oncotarget"},{"key":"2647_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinimag.2022.04.003","volume":"87","author":"JN Thai","year":"2022","unstructured":"Thai JN, et al. Low correlation between serum thyroglobulin and 131I radioiodine whole-body scintigraphy: implication for postoperative disease surveillance in differentiated thyroid cancer. Clin Imaging. 2022;87:1\u20134.","journal-title":"Clin Imaging"},{"key":"2647_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/00003072-200412000-00005","volume":"29","author":"PW Souza Ros\u00e1rio","year":"2004","unstructured":"Souza Ros\u00e1rio PW, et al. Post-I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med. 2004;29:795\u20138.","journal-title":"Clin Nucl Med"},{"key":"2647_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s12149-009-0303-z","volume":"23","author":"S Iwano","year":"2009","unstructured":"Iwano S, et al. Comparisons of I-123 diagnostic and I-131 post-treatment scans for detecting residual thyroid tissue and metastases of differentiated thyroid cancer. Ann Nucl Med. 2009;23:777\u201382.","journal-title":"Ann Nucl Med"},{"key":"2647_CR12","first-page":"629","volume":"78","author":"SI Sherman","year":"1994","unstructured":"Sherman SI, et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab. 1994;78:629\u201334.","journal-title":"J Clin Endocrinol Metab"},{"key":"2647_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1089\/thy.2000.10.573","volume":"10","author":"V Fatourechi","year":"2000","unstructured":"Fatourechi V, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid. 2000;10:573\u20137.","journal-title":"Thyroid"},{"key":"2647_CR14","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1530\/EJE-11-0156","volume":"164","author":"R Ciappuccini","year":"2011","unstructured":"Ciappuccini R, et al. Postablation 131I scintigraphy with neck and thorax SPECT\/CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer. Eur J Endocrinol. 2011;164:961\u20139.","journal-title":"Eur J Endocrinol"},{"key":"2647_CR15","doi-asserted-by":"crossref","first-page":"N15","DOI":"10.2967\/jnumed.121.262402","volume":"63","author":"AM Avram","year":"2022","unstructured":"Avram AM, et al. SNMMI procedure standard\/EANM practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: abbreviated version. J Nucl Med. 2022;63:N15\u201335.","journal-title":"J Nucl Med"},{"key":"2647_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5772\/26287","volume-title":"12 Chapters on Nuclear Medicine","author":"HC Song","year":"2011","unstructured":"Song HC, Chong A. Post-therapeutic I-131 whole-body scan in patients with differentiated thyroid cancer. In: Gholamrezanezhad A, editor. 12 Chapters on Nuclear Medicine. Rijeka: InTech; 2011. pp. 231\u201350. https:\/\/doi.org\/10.5772\/26287."},{"key":"2647_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","volume":"35","author":"MD Ringel","year":"2025","unstructured":"Ringel MD, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid. 2025;35:841\u2013985.","journal-title":"Thyroid"},{"key":"2647_CR18","doi-asserted-by":"crossref","unstructured":"Pacini F et al. 2022 ETA consensus statement: what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J. 2022;11.","DOI":"10.1530\/ETJ-21-0046"},{"issue":"Suppl 1","key":"2647_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cen.12515","volume":"81","author":"P Perros","year":"2014","unstructured":"Perros P, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81(Suppl 1):1\u2013122.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2647_CR20","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1590\/S0004-27302009000700014","volume":"53","author":"F Pitoia","year":"2009","unstructured":"Pitoia F, et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2009;53:884\u20137.","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"2647_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1507\/endocrj.EJ24-0644","volume":"72","author":"I Sugitani","year":"2025","unstructured":"Sugitani I, et al. The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery. Endocr J. 2025;72:545\u2013635.","journal-title":"Endocr J"},{"key":"2647_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2967\/jnumed.119.240945","volume":"61","author":"KJ Donohoe","year":"2020","unstructured":"Donohoe KJ, et al. Appropriate use criteria for nuclear medicine in the evaluation and treatment of differentiated thyroid cancer. J Nucl Med. 2020;61:375\u201396.","journal-title":"J Nucl Med"},{"key":"2647_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s13139-010-0051-y","volume":"44","author":"A Chong","year":"2010","unstructured":"Chong A, et al. Improved detection of lung or bone metastases with an I-131 whole-body scan on the 7th day after high-dose I-131 therapy in patients with thyroid cancer. Nucl Med Mol Imaging. 2010;44:273\u201381.","journal-title":"Nucl Med Mol Imaging"},{"key":"2647_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12149-011-0486-y","volume":"25","author":"JW Lee","year":"2011","unstructured":"Lee JW, et al. Comparison of 131I whole-body scans on the third and tenth day after 131I therapy in patients with well-differentiated thyroid cancer: preliminary report. Ann Nucl Med. 2011;25:439\u201346.","journal-title":"Ann Nucl Med"},{"key":"2647_CR25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/RLU.0b013e3181a345be","volume":"34","author":"BT Hung","year":"2009","unstructured":"Hung BT, et al. Appropriate time for post-therapeutic I-131 whole-body scan. Clin Nucl Med. 2009;34:339\u201342.","journal-title":"Clin Nucl Med"},{"key":"2647_CR26","doi-asserted-by":"publisher","first-page":"955387","DOI":"10.3389\/fendo.2022.955387","volume":"13","author":"S Liu","year":"2022","unstructured":"Liu S, et al. A semiquantitative study of the optimal whole-body imaging time after 131I therapy for differentiated thyroid cancer. Front Endocrinol (Lausanne). 2022;13:955387.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2647_CR27","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/MNM.0b013e328363cc5c","volume":"34","author":"M Salvatori","year":"2013","unstructured":"Salvatori M, et al. Determining the appropriate time of execution of an I-131 post-therapy whole-body scan: comparison between early and late imaging. Nucl Med Commun. 2013;34:900\u20138.","journal-title":"Nucl Med Commun"},{"key":"2647_CR28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/RLU.0b013e3182444286","volume":"37","author":"N Kodani","year":"2012","unstructured":"Kodani N, et al. Utility of additional delayed post-therapeutic 131I whole-body scanning in patients with thyroid cancer. Clin Nucl Med. 2012;37:264\u20137.","journal-title":"Clin Nucl Med"},{"key":"2647_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.23736\/S1824-4785.18.03074-1","volume":"64","author":"L Qiu","year":"2020","unstructured":"Qiu L, et al. Comparison of post-therapeutic sequential 131I whole-body scans in the detection of metastatic thyroid cancer. Q J Nucl Med Mol Imaging. 2020;64:313\u201320.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"2647_CR30","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4103\/ijnm.ijnm_133_24","volume":"39","author":"P Kumar","year":"2024","unstructured":"Kumar P, Bal C, Damle NA. Optimal time of diagnostic and posttherapeutic iodine-131 whole-body scan in postoperative pediatric and young adult differentiated thyroid cancer patients. Indian J Nucl Med. 2024;39:428\u201335.","journal-title":"Indian J Nucl Med"},{"key":"2647_CR31","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1007\/s00259-023-06295-0","volume":"50","author":"J Taprogge","year":"2023","unstructured":"Taprogge J, et al. Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multicentre multinational Horizon 2020 MEDIRAD project. Eur J Nucl Med Mol Imaging. 2023;50:3225\u201334.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2647_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-1-4939-3314-3_12","volume-title":"Thyroid Cancer: A Comprehensive Guide to Clinical Management","author":"D Van Nostrand","year":"2016","unstructured":"Van Nostrand D, Atkins FB. Primer and atlas for the interpretation of radioiodine whole-body scintigraphy. In: Wartofsky L, Van Nostrand D, editors. Thyroid Cancer: A Comprehensive Guide to Clinical Management. New York: Springer; 2016. pp. 153\u201384."},{"issue":"12","key":"2647_CR33","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1089\/thy.2015.0173","volume":"25","author":"GB Coura-Filho","year":"2015","unstructured":"Coura-Filho GB, Willegaignon J, Buchpiguel CA, Sapienza MT. Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer. Thyroid. 2015;25(12):1291\u20136. https:\/\/doi.org\/10.1089\/thy.2015.0173. Epub 2015 Nov 5. PMID: 26446582.","journal-title":"Thyroid"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-026-02647-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02647-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02647-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T13:06:37Z","timestamp":1786280797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12880-026-02647-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2647"],"URL":"https:\/\/doi.org\/10.1186\/s12880-026-02647-y","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The MEDIRAD study was approved by Institutional Ethics Committee of Philipps University Marburg (reference 83\/19) and registered in EudraCT (2019-002244-25). All participants provided written informed consent for participation in the MEDIRAD study. The present retrospective secondary analysis was approved by the Institutional Ethics Committee of Philipps University Marburg (reference 26\u2013155 RS; 30 April 2026), and the requirement for additional consent was waived.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"388"}}